

Walker ChandioK & Co LLP

Walker ChandioK & Co LLP

L 41, Connaught Circus,
Outer Circle,
New Delhi – 110 001
India

T +91 11 45002219
F +91 11 42787071

Independent Auditor's Report on Annual Financial Results of Jagsonpal Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jagsonpal Pharmaceuticals Limited

Opinion

1. We have audited the accompanying annual financial results ('the Statement') of Jagsonpal Pharmaceuticals Limited ('the Company') for the year ended 31 March 2024, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2024.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion



Walker Chandiook & Co LLP

Independent Auditor's Report on Annual Financial Results of Jagsonpal Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd.)

Responsibilities of Management and Those Charged with Governance for the Statement

4. This Statement has been prepared on the basis of the annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;



Walker Chandiook & Co LLP

Independent Auditor's Report on Annual Financial Results of Jagsonpal Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd.)

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure, and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended 31 March 2024, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No.: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani
Partner
Membership No. 517440



UDIN: 24517440BKGZTU4702

Place: Gurugram
Date: 20 May 2024

Jagsonpal Pharmaceuticals Limited

Corporate office: Plot No. 412-415,3rd Floor, Nimai Tower, Phase- IV, Udyog Vihar, Sector 18, Gurugram, Haryana-122015

CIN No:- L74899DL1978PLC009181

Phone: 0124-4406710

Statement of Audited Financial Results for the Quarter and Year Ended 31 March 2024

(Rs. in Million)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31 March (Audited) (Refer note 8)	31 December (Unaudited)	31 March (Audited) (Refer note 8)	31 March (Audited)	31 March (Audited)
		2024	2023	2023	2024	2023
	INCOME					
1	Revenue from operations	434.86	472.34	554.51	2,087.02	2,367.14
2	Other income	24.87	25.21	25.59	92.79	57.34
3	Total income [1+2]	459.73	497.55	580.10	2,179.81	2,424.48
4	EXPENSES					
	a) Cost of materials consumed	37.88	58.80	63.19	221.00	312.14
	b) Purchases of stock-in-trade	120.64	139.84	176.56	539.81	568.30
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	18.12	(2.92)	(16.15)	38.96	43.02
	d) Employee benefits expense	114.46	116.42	132.09	484.93	564.15
	e) Share based payment expense	22.74	26.52	39.25	133.10	87.65
	f) Finance costs	2.17	2.26	1.96	8.14	4.13
	g) Depreciation and amortisation expense	4.03	4.12	4.79	16.63	12.05
	h) Other expenses	94.33	99.72	105.20	438.55	450.37
	Total expenses	414.37	444.76	506.89	1,881.12	2,041.81
5	Profit before exceptional items and tax (3-4)	45.36	52.79	73.21	298.69	382.67
6	Exceptional items	-	-	-	-	34.59
7	Profit before tax (5-6)	45.36	52.79	73.21	298.69	348.08
8	Tax expense:					
	Current tax (including earlier years)	10.04	13.72	15.40	75.60	76.32
	Deferred tax charge/(credit)	(0.17)	(0.56)	1.79	(1.54)	4.55
9	Net profit for the period/year (7-8)	35.49	39.63	56.02	224.63	267.21
10	Other comprehensive income (OCI)					
	i) a) Items that will not be reclassified to profit or loss	(2.55)	1.52	(0.78)	2.67	(108.86)
	b) Income tax relating to items that will not be reclassified to profit or loss	0.67	(0.40)	0.18	(0.64)	15.31
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
11	Total comprehensive income for the period/year (9+10)	33.61	40.75	55.42	226.66	173.66
12	Earnings per share (not annualised for the quarters)					
	Basic (Rs.)	1.31	1.48	2.14	8.49	10.20
	Diluted (Rs.)	1.31	1.47	2.14	8.46	10.20
13	Paid-up equity share capital (face value per share Rs. 5)	132.19	131.44	130.99	132.19	130.99
14	Reserves excluding revaluation reserves (other equity)	-	-	-	1,741.83	1,457.91
	See accompanying notes to the Audited Financial Results					



**SIGNED FOR
IDENTIFICATION
PURPOSES ONLY**



Manish


Jagsonpal Pharmaceuticals Limited
Statement of Audited Assets and Liabilities

(Rs. in Million)

Sr. No.	Particulars	As at	
		31 March	31 March
		(Audited)	(Audited)
		2024	2023
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	9.10	183.50
	Right of use assets	83.92	59.28
	Financial assets		
	Investments	-	11.21
	Other financial assets	51.70	26.44
	Income-tax assets (net)	12.46	3.12
	Other non-current assets	21.06	20.32
	Total non-current assets	178.24	303.87
2	Current assets		
	Inventories	149.97	206.76
	Financial assets		
	Trade receivables	109.51	208.72
	Cash and cash equivalents	127.60	110.53
	Bank balances other than cash and equivalents above	1,351.74	1,035.73
	Other financial assets	1.10	3.15
	Other current assets	80.83	80.70
	Assets held for sale	171.79	-
	Total current assets	1,992.54	1,645.59
	Total assets	2,170.78	1,949.46
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	132.19	130.99
	Other equity	1,741.83	1,457.91
	Total equity	1,874.02	1,588.90
2	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Lease liabilities	75.57	52.47
	Provisions	9.18	10.75
	Deferred tax liabilities (net)	20.73	21.63
	Total non-current liabilities	105.48	84.85
	Current liabilities		
	Financial liabilities		
	Lease liabilities	13.84	7.54
	Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	16.44	29.33
	Total outstanding dues of creditors other than micro enterprises and small enterprises	59.52	136.47
	Other financial liabilities	67.14	77.44
	Other current liabilities	26.82	20.98
	Provisions	7.52	3.76
	Current tax liabilities (net)	-	0.19
	Total current liabilities	191.28	275.71
	Total equity and liabilities	2,170.78	1,949.46



SIGNED FOR
IDENTIFICATION
PURPOSES ONLY



Jagsonpal Pharmaceuticals Limited
Statement of Audited Cash Flows

(Rs. in Million)

Particulars	Year Ended	
	31 March	31 March
	(Audited)	(Audited)
	2024	2023
A. Cash flows from operating activities		
Profit before tax	298.69	348.08
Adjustments:		
Depreciation and amortisation expense	16.63	12.05
Exceptional items	-	27.79
Interest income	(85.92)	(34.28)
Finance costs	8.14	4.13
Share based payment expense	133.10	87.65
Profit on sale of property, plant and equipment	-	(3.59)
Loss on fair valuation of financial assets	-	4.44
Profit on sale of current and non-current Investments	-	(5.92)
Allowance for expected credit loss	7.67	2.62
Excess provisions written back	(0.60)	(2.42)
Provision for inventory obsolescence	3.69	3.80
	82.71	96.27
Operating cash flows before working capital changes	381.40	444.35
Movement in working capital:		
Trade receivables	91.54	(55.56)
Other current and non-current assets	(34.65)	81.75
Inventories	53.10	86.86
Other current and non-current financial assets	1.16	(19.12)
Trade payables	(89.82)	(19.62)
Other current financial and non-financial liabilities	31.87	23.60
Provisions	2.19	(2.95)
Cash flows from operations	436.79	539.31
Income-tax paid (net of refund)	(85.13)	(72.76)
Net cash flows from operating activities (A)	351.66	466.55
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(2.48)	(3.18)
Proceeds from sale of property, plant and equipment	-	12.96
Proceeds from sale of long-term investments	11.46	196.87
Movement in current investments (net)	-	215.33
Investment in bank deposits	(1,354.07)	(1,058.93)
Proceeds from bank deposits	1,025.94	25.97
Interest received	73.67	34.28
Net cash used in investing activities (B)	(245.48)	(576.71)
C. Cash flows from financing activities		
Proceeds from issue of equity share capital (including securities premium)	56.35	-
Finance costs paid	(0.37)	(1.35)
Payment for principal portion of lease liabilities	(6.33)	(0.44)
Payment for interest portion of lease liabilities	(7.77)	(2.78)
Dividend paid	(130.99)	-
Net cash used in financing activities (C)	(89.11)	(4.57)
Net decrease in cash and cash equivalents (A+B+C)	17.07	(114.73)
Add: cash and cash equivalents at the beginning of the year	110.53	225.26
Cash and cash equivalents at the end of the year	127.60	110.53
Reconciliation of cash and cash equivalents as per the statement of cash flow		
Balance with banks in current accounts	57.50	109.99
Cash on hand	-	0.54
Bank deposits with original maturity less than three months	70.10	-
Cash and cash equivalents at the end of the year	127.60	110.53



SIGNED FOR
IDENTIFICATION
PURPOSES ONLY



Manish

Notes to the audited financial results:

1. The above financial results of Jagsonpal Pharmaceuticals Limited (the 'Company') for the quarter and year ended on 31 March 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 20 May 2024. These financial results for the year ended 31 March 2024 have been audited by statutory auditors.
2. These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
3. The Company is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to its customers in India and overseas, which is being considered as a single reportable business segment by the chief operating decision maker.
4. Subsequent to quarter and year-end, on 16 May 2024, the Company has entered into a business transfer agreement ('Agreement') for the purchase of Dermatology and Childcare divisions (India and Bhutan location) of Yash Pharma Laboratories Private Limited. The said Agreement is subject to certain closing conditions and will be accounted for accordingly.
5. During the year ended 31 March 2024, the management of the Company suspected availability of counterfeit Indocap SR, one of the products of the Company in select territories. Subsequently, the Company lodged a First Information Report ('FIR') regarding this matter with the Uttarakhand Police Department ('Police Department'). The Police Department acted quickly which led to discovery and closure of the factory where such counterfeit product was being manufactured along with the arrest of the accused (including an ex-employee of the Company). The Uttarakhand State Government ('Petitioner') has filed a criminal case with the fast-track court ('the Court') in Dehradun against the accused, and the state's legal counsel is representing the case before the Court. Based on the FIR, the Police Department has submitted the chargesheet on 11 January 2024. The Company is attending the Court proceeding as required, especially for presenting witness statements. The availability of counterfeit product in the market may have impacted the sale of original product, however, the amount of potential loss caused to the Company is unascertainable.
6. The Board of Directors at their meeting held on 20 May 2024 have recommended a final dividend of ₹ 5 per equity share (of ₹ 5 each) amounting to ₹ 132.19 million for the year ended 31 March 2024 subject to approval in Annual General Meeting.
7. During the quarter, the Company has allotted 150,000 equity shares under the Company's Employee Stock Option Plan 2022 on exercise of vested options by eligible employees.
8. The figures for the quarter ended 31 March 2024 and quarter ended 31 March 2023, as reported in the financial results, are the balancing figures between the audited figures for the year ended 31 March 2024 and 31 March 2023 and the published year to date figures for 31 December 2023 and 31 December 2022, which were subjected to limited review by the statutory auditors.
9. Previous periods figures have been regrouped/reclassified wherever necessary.

Place : Gurugram
Date : 20 May 2024



Manish Gupta
Managing Director



**SIGNED FOR
IDENTIFICATION
PURPOSES ONLY**

